Scientific work

Doç. Dr. Muhammed Mustafa Atcı

72 publications. The source of the information is stated next to each publication.

Back to profile

  1. Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-15725-9 PMID 41691201 Open-access full textSource: OpenAlex

  2. Perioperative FLOT versus Definitive 50.4 Gy Chemoradiotherapy in Siewert II Esophagogastric Junction Adenocarcinoma: A Multicenter Retrospective Cohort Study

    Cancer Management and Research, 2026

    DOI 10.2147/cmar.s583473 PMID 42038552 Open-access full textSource: OpenAlex

  3. Expression and prognostic importance of lymphocyte activation gene 3 and CD73 in advanced or metastatic hepatocellular carcinoma

    Journal of International Medical Research, 2026

    DOI 10.1177/03000605251386599 PMID 41521150 Open-access full textSource: OpenAlex

  4. Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature

    Clinical Genitourinary Cancer, 2026

    DOI 10.1016/j.clgc.2026.102594 PMID 42349378 Source: OpenAlex

  5. De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world study

    The Breast, 2026

    DOI 10.1016/j.breast.2026.104838 PMID 42309024 Open-access full textSource: OpenAlex

  6. Prognostic factors and survival outcomes in older adults with extensive-stage small cell lung cancer: A multicenter retrospective cohort study

    Medicine, 2026

    DOI 10.1097/md.0000000000048711 PMID 42116366 Open-access full textSource: OpenAlex

  7. Prognostic value of PSMA PET–derived tumor volume in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide

    Cancer Imaging, 2026

    DOI 10.1186/s40644-026-01036-6 PMID 42063136 Open-access full textSource: OpenAlex

  8. Inflammatory and Nutritional Indices as Prognostic Markers in Locally Advanced Gastric Cancer Treated with Neoadjuvant FLOT: A Retrospective Multicenter Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15072574 PMID 41976874 3 citations (Europe PMC) Open-access full textSource: OpenAlex

  9. Neoadjuvant anthracycline-free versus anthracycline-containing chemotherapy combined with dual HER2 blockade in HER2-positive breast cancer: a real-world comparative study

    Breast Cancer Research, 2026

    DOI 10.1186/s13058-026-02312-w PMID 42210329 Open-access full textSource: OpenAlex

  10. Neoadjuvant Pertuzumab in Breast Cancer and Associated Prognostic Factors

    European Archives of Medical Research, 2026

    DOI 10.14744/eamr.2025.35682 Open-access full textSource: OpenAlex

  11. Efficacy and tolerability of CDK 4/6 inhibitors in HR-positive HER2-negative de novo metastatic breast cancer patients aged ≥ 70 years

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16430-3 PMID 42351034 Open-access full textSource: OpenAlex

  12. Maintenance pemetrexed after platinum pemetrexed chemotherapy and survival outcomes in malignant pleural mesothelioma in a multicenter real world study

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-61625-0 PMID 42457832 Open-access full textSource: OpenAlex

  13. Bevacizumab or Aflibercept in Combination with Second-Line FOLFIRI after Progression on FOLFOX Plus Bevacizumab in Metastatic Colorectal Cancer: A Comparative Study

    Journal of Cancer, 2026

    DOI 10.7150/jca.138530 PMID 42807710 Open-access full textSource: OpenAlex

  14. Treatment outcomes of sunitinib and/or pazopanib in advanced alveolar soft part sarcoma: A Turkish Oncology Group (TOG) study

    Scientific Reports, 2025

    DOI 10.1038/s41598-025-29276-9 PMID 41315659 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  15. Factors affecting survival and prognosis in extensive stage small cell lung cancer

    BMC Pulmonary Medicine, 2025

    DOI 10.1186/s12890-025-03625-w PMID 40200252 8 citations (Europe PMC) Open-access full textSource: OpenAlex

  16. Comparison of clinical and prognostic characteristics of patients with classic and AIDS-related Kaposi sarcoma: A single-center experience

    Medicine, 2025

    DOI 10.1097/md.0000000000043576 PMID 40760592 Open-access full textSource: OpenAlex

  17. Distribution of side effects of anti-EGFR treatments in patients with metastatic colorectal cancer and evaluation of their relationship with survival

    Anti-Cancer Drugs, 2025

    DOI 10.1097/cad.0000000000001755 PMID 40626459 1 citation (Europe PMC) Source: OpenAlex

  18. Bevacizumab Efficacy and Tolerability in Patients with Metastatic Platinum-Sensitive Ovarian Cancer Beyond Progression

    Cancer Management and Research, 2025

    DOI 10.2147/cmar.s531276 PMID 40861079 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  19. The Effect of Total Neoadjuvant Treatment on Pathological Response and Survival in Locally Advanced Rectal Cancer: A Single Center Experience

    Clinical Colorectal Cancer, 2025

    DOI 10.1016/j.clcc.2025.05.001 PMID 40537334 1 citation (Europe PMC) Source: OpenAlex

  20. Advancing prognostic precision in unplanned oncology admissions: the promise of the PROMISE–CTI score

    The Lancet Regional Health - Europe, 2025

    DOI 10.1016/j.lanepe.2025.101336 PMID 40530357 Open-access full textSource: OpenAlex

  21. Analysis of the impact of IMDC score parameters on patients with metastatic clear cell renal cell carcinoma

    Biomarkers in Medicine, 2025

    DOI 10.1080/17520363.2025.2589382 PMID 41243728 Source: OpenAlex

  22. Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study

    Scientific Reports, 2025

    DOI 10.1038/s41598-025-87553-z PMID 39863702 Open-access full textSource: OpenAlex

  23. Distinguishing between carcinoid tumors and hamartomas: the diagnostıc value of FDG PET/CT

    The Egyptian Journal of Radiology and Nuclear Medicine, 2025

    DOI 10.1186/s43055-025-01629-4 Open-access full textSource: OpenAlex

  24. 198P Association of ovarian function suppression with distant disease-free survival in premenopausal-patients with HR+HER2+ localized breast cancer: A retrospective study in 26 sites

    ESMO Open, 2025

    DOI 10.1016/j.esmoop.2025.104752 Open-access full textSource: OpenAlex

  25. Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer

    BMC Cancer, 2024

    DOI 10.1186/s12885-023-11783-5 PMID 38166764 6 citations (Europe PMC) Open-access full textSource: OpenAlex

  26. Perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in gastric cancer: Pathological regression grade and its relationship to clinical outcome

    Indian Journal of Cancer, 2024

    DOI 10.4103/ijc.ijc_1283_20 PMID 39960699 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  27. Factors Affecting Recurrence and Survival in Stage IIA Colon Cancer Patients

    Oncology, 2024

    DOI 10.1159/000540334 PMID 39008971 3 citations (Europe PMC) Source: OpenAlex

  28. Evaluation of ixabepilone efficacy and tolerability in metastatic breast cancer

    Medicine, 2024

    DOI 10.1097/md.0000000000040649 PMID 39809199 4 citations (Europe PMC) Open-access full textSource: OpenAlex

  29. The impact of body mass index on the progression-free survival of CDK 4/6 inhibitors in metastatic breast cancer patients

    Future Oncology, 2024

    DOI 10.1080/14796694.2024.2402212 PMID 39316555 8 citations (Europe PMC) Open-access full textSource: OpenAlex

  30. The Optimal Treatment Approaches and Prognostic Factors In Elderly Patients with Advanced Stage Biliary Tract Tumors

    Acta Oncologica Turcica, 2023

    DOI 10.5505/aot.2023.03708 Open-access full textSource: OpenAlex

  31. Major and minor salivary gland cancers: A multicenter retrospective study

    Head & Neck, 2023

    DOI 10.1002/hed.27376 PMID 37084179 8 citations (Europe PMC) Open-access full textSource: OpenAlex

  32. Real-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective study

    Neoplasma, 2023

    DOI 10.4149/neo_2022_221004n984 PMID 36620878 Open-access full textSource: OpenAlex

  33. Prognostic significance of mucinous histology in left‑sided metastatic colorectal cancers with wild‑type RAS and evaluation of backbone chemotherapy regimens

    Oncology Letters, 2023

    DOI 10.3892/ol.2023.13795 PMID 37123028 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  34. Initial Albumin-Bilirubin Grade as a Prognostic Indicator of Pancreatic Cancer with Liver Metastasis

    Journal of Oncological Sciences, 2023

    DOI 10.37047/jos.2021-87242 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  35. Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study

    Journal of Cancer Research and Clinical Oncology, 2022

    DOI 10.1007/s00432-022-03984-5 PMID 35381885 3 citations (Europe PMC) Open-access full textSource: OpenAlex

  36. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer

    Current Medical Research and Opinion, 2022

    DOI 10.1080/03007995.2022.2108619 PMID 35916475 4 citations (Europe PMC) Source: OpenAlex

  37. First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal carcinoma

    Bosnian Journal of Basic Medical Sciences, 2022

    DOI 10.17305/bjbms.2021.7069 PMID 35460397 4 citations (Europe PMC) Open-access full textSource: OpenAlex

  38. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?

    Expert Review of Anticancer Therapy, 2022

    DOI 10.1080/14737140.2022.2076670 PMID 35543015 3 citations (Europe PMC) Source: OpenAlex

  39. Effect of Adjuvant Chemotherapy in Stage III Cervical Cancer Patients Treated with Concurrent Chemoradiation: A Multicenter Study

    Oncology Research and Treatment, 2022

    DOI 10.1159/000521980 PMID 35034017 3 citations (Europe PMC) Source: OpenAlex

  40. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

    Journal of Cancer Research and Clinical Oncology, 2022

    DOI 10.1007/s00432-022-04252-2 PMID 36048274 5 citations (Europe PMC) Open-access full textSource: OpenAlex

  41. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study

    Future Oncology, 2022

    DOI 10.2217/fon-2022-0083 PMID 35734870 3 citations (Europe PMC) Open-access full textSource: OpenAlex

  42. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study

    Journal of Chemotherapy, 2022

    DOI 10.1080/1120009x.2022.2040770 PMID 35174772 Open-access full textSource: OpenAlex

  43. Efficacy of Imatinib on Advanced and Refractory Desmoid Tumors: A Retrospective Study

    Journal of Oncological Sciences, 2022

    DOI 10.37047/jos.2021-87391 Open-access full textSource: OpenAlex

  44. Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study.

    Journal of Clinical Oncology, 2022

    DOI 10.1200/jco.2022.40.4_suppl.202 Source: OpenAlex

  45. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study

    Anti-Cancer Drugs, 2022

    DOI 10.1097/cad.0000000000001310 PMID 35703239 3 citations (Europe PMC) Source: OpenAlex

  46. FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer

    Journal of Chemotherapy, 2022

    DOI 10.1080/1120009x.2022.2026125 PMID 35037592 15 citations (Europe PMC) Source: OpenAlex

  47. Dynamic changes in systemic immune‐inflammation index predict pathological tumor response and overall survival in patients with gastric or gastroesophageal junction cancer receiving neoadjuvant chemotherapy

    Asia-Pacific Journal of Clinical Oncology, 2022

    DOI 10.1111/ajco.13784 PMID 35538045 17 citations (Europe PMC) Source: OpenAlex

  48. A new biomarker for lung metastasis in non-seminomatous testicular cancer: De Ritis Ratio

    Aktuelle Urologie, 2022

    DOI 10.1055/a-1926-9698 PMID 36302549 3 citations (Europe PMC) Source: OpenAlex

  49. The Relationship Between Poor Glycaemic Control and Risk Factors in Patients with Type 2 Diabetes Mellitus

    Eurasian Journal of Medical Advances, 2022

    DOI 10.14744/ejma.2022.87597 3 citations (OpenAlex) Open-access full textSource: OpenAlex

  50. Effects of a COVID-19 Pandemic on Breast Cancer Management

    European Archives of Medical Research, 2022

    DOI 10.4274/eamr.galenos.2021.92063 Open-access full textSource: OpenAlex